Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Core Insights - Cardiol Therapeutics has received a Notice of Allowance for a U.S. patent that will protect its heart drugs until late 2040, specifically for CardiolRx™ and CRD-38 in treating various cardiac conditions [2][3][5] Intellectual Property Protection - The new patent will provide broad intellectual property protection for Cardiol's therapies against a range of heart diseases, including heart failure, myocarditis, and atherosclerosis [2][5] - This patent allowance enhances Cardiol's market position and intellectual property portfolio, complementing its existing U.S. Orphan Drug Designation for pericarditis [3][5] Clinical Development Programs - Cardiol is advancing late-stage clinical programs for recurrent pericarditis and acute myocarditis, addressing significant unmet medical needs [3][9] - The company is preparing to initiate first-in-human clinical evaluations of CRD-38, a novel therapy for inflammatory heart disease, including heart failure [3][9] Upcoming Presentations and Trials - Cardiol plans to present comprehensive data from the ARCHER trial, a Phase II study of CardiolRx™ in acute myocarditis, at the European Society of Cardiology Annual Meeting on November 29 [3][8] - An update on the pivotal Phase III MAVERIC trial in recurrent pericarditis will also be provided as patient enrollment accelerates [3][7]